Labcorp (LH)
(Delayed Data from NYSE)
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Has LabCorp (LH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.
Smith+Nephew (SNN) Rolls Out Robotic Assisted Surgical System
by Zacks Equity Research
Smith+Nephew's (SNN) CORI system enables each patient to have a knee replacement that is shape-matched and aligned to their specific anatomy.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption
by Zacks Equity Research
Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.
Illumina's (ILMN) New Alliance to Accelerate Genomics in China
by Zacks Equity Research
Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.
Veeva Systems (VEEV) Digital Tools Boost Patient Engagement
by Zacks Equity Research
Veeva Systems' (VEEV) enhancements in digital tools incorporate new ways for seamless communication among healthcare providers and field teams.
LH vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Zimmer Biomet's (ZBH) Recovery Slows in Americas Amid Pandemic
by Zacks Equity Research
The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).
CVS Health's (CVS) New Measures to Boost Omnichannel Health
by Zacks Equity Research
CVS Health's (CVS) new measures will support its strategy of making health care more affordable, accessible and convenient for consumers.
LabCorp (LH) to Expand Nonclinical Development With New Buyout
by Zacks Equity Research
LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.
Phibro (PAHC) Sales Hurt by Staffing Shortage Amid Pandemic
by Zacks Equity Research
Internationally, Phibro (PAHC) is registering growth in nutritional specialties driven by strong sales of dairy products.
Thermo Fisher (TMO) New Facility to Advance Lab Products Supply
by Zacks Equity Research
Thermo Fisher's (TMO) new manufacturing facility will help the United States meet demand surges for vital laboratory products.
Bruker (BRKR) Advances in Proteomics Workflow With New Pacts
by Zacks Equity Research
Talking about these three developments, Bruker (BRKR) notes that because of complex sample preparation protocols, the widespread adoption of proteomics has been limited.
Illumina (ILMN) iHope Genetic Health Program Expands WGS Access
by Zacks Equity Research
Illumina's (ILMN) launch of iHope Genetic Health program will expand access to WGS to low- and middle-income communities worldwide.
Abbott (ABT) Introduces New Next-Generation Infant Formula
by Zacks Equity Research
Abbott's (ABT) Similac 360 Total Care contains five different HMOs, similar to human breast milk, to support the health and development of an infant.
SmileDirectClub (SDC) Introduces Treatment Planning Software
by Zacks Equity Research
SmileDirectClub's (SDC) SmileOS will enable its affiliated network of state-licensed doctors to treat more patients, better predict tooth movements and visualize patients' treatment.
Here's Why You Should Retain STERIS (STE) Stock For Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to its strong fiscal second-quarter results and bullish 2022 outlook.
Medtronic's (MDT) PillCam SB3 System Gets 510 (k) Clearance
by Zacks Equity Research
Medtronic's (MDT) PillCam SB3 System provides a convenient option for a contactless procedure and helps ensure that patients can access care promptly.
Abbott (ABT) Aveir System Meets Primary Pivotal Trial Endpoints
by Zacks Equity Research
Abbott's (ABT) Aveir pacing system has the potential to advance treatment for patients who need a pacemaker but where physicians are concerned about more invasive surgery.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by consistent recovery across its businesses and raised 2021 guidance.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong third-quarter results and bullish 2021 guidance.
Omnicell (OMCL) Inks New Deal to Manage Controlled Substances
by Zacks Equity Research
Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Robust performance across the Roto-Rooter segment and sequential growth in VITAS admissions are driving the top line for Chemed (CHE).
NuVasive (NUVA) Q3 Earnings Miss Estimates, 2021 Guidance Down
by Zacks Equity Research
NuVasive (NUVA) reported lower-than-expected earnings and revenues with COVID-led headwinds and healthcare staffing shortages dampening the Q3 top-line growth.